Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2012

Global Markets Direct, March 2012, Pages: 205

Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2012', provides an overview of the Chronic Lymphocytic Leukemia (CLL) therapeutic pipeline. This report provides information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL). 'Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chronic Lymphocytic Leukemia (CLL).
- A review of the Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Chronic Lymphocytic Leukemia (CLL) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Chronic Lymphocytic Leukemia (CLL) Therapeutic Products under Development, Key Players in Chronic Lymphocytic Leukemia (CLL) Therapeutics, Chronic Lymphocytic Leukemia (CLL) Pipeline Overview, Chronic Lymphocytic Leukemia (CLL) Pipeline, Chronic Lymphocytic Leukemia (CLL) Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chronic Lymphocytic Leukemia (CLL) Overview
Therapeutics Development
An Overview of Pipeline Products for Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia (CLL) Therapeutics under Development by Companies
Chronic Lymphocytic Leukemia (CLL) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Chronic Lymphocytic Leukemia (CLL) Therapeutics – Products under Development by Companies
Chronic Lymphocytic Leukemia (CLL) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Chronic Lymphocytic Leukemia (CLL) Therapeutics Development
Bristol-Myers Squibb Company
Genzyme Corporation
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Kyowa Hakko Kirin Co., Ltd.
Abbott Laboratories
Amgen Inc.
Sanofi-Aventis
AstraZeneca PLC
GlaxoSmithKline plc
Genentech, Inc.
Gilead Sciences, Inc.
Merck & Co., Inc.
Emergent BioSolutions Inc.
Lentigen Corporation
Micromet, Inc.
Celltrion, Inc.
BioMarin Pharmaceutical Inc.
Cephalon, Inc.
ImmunoGen, Inc.
Nippon Shinyaku Co., Ltd.
SuperGen, Inc.
Genmab A/S
Santaris Pharma A/S
Celgene Corporation
Bayer AG
4SC AG
Celldex Therapeutics, Inc.
IMMUNOMEDICS, INC
InNexus Biotechnology Inc.
MethylGene Inc
Keryx Biopharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc.
Portola Pharmaceuticals, Inc.
TopoTarget A/S
Pharmacyclics, Inc.
MorphoSys AG
Threshold Pharmaceuticals, Inc.
InDex Pharmaceuticals AB
Memgen, LLC.
Curacyte AG
Ascenta Therapeutics, Inc.
Arno Therapeutics, Inc.
Semafore Pharmaceuticals, Inc.
Avila Therapeutics, Inc.
Polyphenon Pharma
Onconova Therapeutics, Inc
NOXXON Pharma AG
SBI Biotech Co., Ltd.
KaloBios Pharmaceuticals, Inc.
Aprea AB.
Cylene Pharmaceuticals, Inc.
Biothera
Nereus Pharmaceuticals, Inc.
Astellas Pharma GmbH
LFB Biotechnologies, S.A.S.U.
KAEL-GemVax
Advancell
Chronic Lymphocytic Leukemia (CLL) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
RG7159 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Arzerra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bendamustine Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Campath + Fludara - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prograf + Methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Cyclophosphamide + Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Cyclophosphamide + Campath - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ofatumumab + Bendamustine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ofatumumab + Chlorambucil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludara + Cytoxan + Rituxan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nipent + Cytoxan + Rituxan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Revlimid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Arzerra + Fludarabine + Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ofatumumab + Chlorambucil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RG7159 + Chlorambucil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Total Body Irradiation + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine Phosphate + Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Fludarabine + Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine Phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Darbepoetin Alfa + Fludarabine Phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Cyclophosphamide + Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chlorambucil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine Phosphate + Mitoxantrone Hydrochloride + Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Procrit - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Cyclophosphamide + Fludarabine Phosphate + Mitoxantrone Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Cyclophosphamide + Fludarabine Phosphate + Mitoxantrone Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Fludarabine Phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Cyclophosphamide + Fludarabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Fludarabine Phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bendamustine + Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allogeneic Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chronic Lymphocytic Leukemia (CLL) Therapeutics – Drug Profile Updates
Chronic Lymphocytic Leukemia (CLL) Therapeutics – Discontinued Products
Chronic Lymphocytic Leukemia (CLL) Therapeutics - Dormant Products
Chronic Lymphocytic Leukemia (CLL) – Product Development Milestones
Featured News & Press Releases
Dec 28, 2011: Emergent Initiates Phase II Study Of TRU-016 In Combination With Bendamustine In Patients With Relapsed Chronic Lymphocytic Leukemia
Dec 14, 2011: Threshold Pharmaceuticals Announces Promising Phase I Clinical Trial Results In Patients With Advanced Leukemias
Dec 13, 2011: Cylene's CX-4945 Demonstrates Encouraging Activity In Several Preclinical Models Of High Risk Leukemias
Dec 13, 2011: Pharmacyclics Announces Updated Results For BTK Inhibitor PCI-32765 For Treatment Of Relapsed Or Refractory Chronic Lymphocytic Leukemia At ASH
Dec 13, 2011: Celgene Announces Final Phase II Data Evaluating REVLIMID And Rituximab In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia
Dec 12, 2011: Aprea Announces Continuation Of Clinical Phase I/II-Study Of APR-246 In Patients With Leukemia
Dec 12, 2011: Avila Therapeutics Presents Data On AVL-292 For Treatment Of B Cell Cancers At 2011 ASH Annual Meeting
Dec 12, 2011: NOXXON Pharma's SDF-1 Inhibitor NOX-A12 Completes Phase I Clinical Trials
Dec 11, 2011: ARIAD Announces Preliminary Data From Pivotal Pace Trial Of Ponatinib
Dec 11, 2011: Interim Study Shows PCI-32765 Is Highly Active In CLL Patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Chronic Lymphocytic Leukemia (CLL), H1 2012
Products under Development for Chronic Lymphocytic Leukemia (CLL) – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Development by Companies, H1 2012 (Contd..3)
Number of Products under Development by Companies, H1 2012 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Development by Companies, H1 2012 (Contd..2)
Products under Development by Companies, H1 2012 (Contd..3)
Products under Development by Companies, H1 2012 (Contd..4)
Products under Development by Companies, H1 2012 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..12)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..13)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..14)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..15)
Bristol-Myers Squibb Company, H1 2012
Genzyme Corporation, H1 2012
Boehringer Ingelheim GmbH, H1 2012
F. Hoffmann-La Roche Ltd., H1 2012
Kyowa Hakko Kirin Co., Ltd., H1 2012
Abbott Laboratories, H1 2012
Amgen Inc., H1 2012
Sanofi-Aventis, H1 2012
AstraZeneca PLC, H1 2012
GlaxoSmithKline plc, H1 2012
Genentech, Inc., H1 2012
Gilead Sciences, Inc., H1 2012
Merck & Co., Inc., H1 2012
Emergent BioSolutions Inc., H1 2012
Lentigen Corporation, H1 2012
Micromet, Inc., H1 2012
Celltrion, Inc., H1 2012
BioMarin Pharmaceutical Inc., H1 2012
Cephalon, Inc., H1 2012
ImmunoGen, Inc., H1 2012
Nippon Shinyaku Co., Ltd., H1 2012
SuperGen, Inc., H1 2012
Genmab A/S, H1 2012
Santaris Pharma A/S, H1 2012
Celgene Corporation, H1 2012
Bayer AG, H1 2012
4SC AG, H1 2012
Celldex Therapeutics, Inc., H1 2012
IMMUNOMEDICS, INC, H1 2012
InNexus Biotechnology Inc., H1 2012
MethylGene Inc, H1 2012
Keryx Biopharmaceuticals, Inc., H1 2012
Alexion Pharmaceuticals, Inc., H1 2012
BioCryst Pharmaceuticals, Inc., H1 2012
Portola Pharmaceuticals, Inc., H1 2012
TopoTarget A/S, H1 2012
Pharmacyclics, Inc., H1 2012
MorphoSys AG, H1 2012
Threshold Pharmaceuticals, Inc., H1 2012
InDex Pharmaceuticals AB, H1 2012
Memgen, LLC., H1 2012
Curacyte AG, H1 2012
Ascenta Therapeutics, Inc., H1 2012
Arno Therapeutics, Inc., H1 2012
Semafore Pharmaceuticals, Inc., H1 2012
Avila Therapeutics, Inc., H1 2012
Polyphenon Pharma, H1 2012
Onconova Therapeutics, Inc, H1 2012
NOXXON Pharma AG, H1 2012
SBI Biotech Co., Ltd., H1 2012
KaloBios Pharmaceuticals, Inc., H1 2012
Aprea AB., H1 2012
Cylene Pharmaceuticals, Inc., H1 2012
Biothera, H1 2012
Nereus Pharmaceuticals, Inc., H1 2012
Astellas Pharma GmbH, H1 2012
LFB Biotechnologies, S.A.S.U., H1 2012
KAEL-GemVax, H1 2012
Advancell, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Chronic Lymphocytic Leukemia (CLL) Therapeutics – Drug Profile Updates
Chronic Lymphocytic Leukemia (CLL) Therapeutics – Discontinued Products
Chronic Lymphocytic Leukemia (CLL) Therapeutics – Discontinued Products (Contd..1)
Chronic Lymphocytic Leukemia (CLL) Therapeutics – Discontinued Products (Contd..2)
Chronic Lymphocytic Leukemia (CLL) Therapeutics – Dormant Products
Chronic Lymphocytic Leukemia (CLL) Therapeutics – Dormant Products (Contd..1)
Chronic Lymphocytic Leukemia (CLL) Therapeutics – Dormant Products (Contd..2)
Chronic Lymphocytic Leukemia (CLL) Therapeutics – Dormant Products (Contd..3)
Chronic Lymphocytic Leukemia (CLL) Therapeutics – Dormant Products (Contd..4)
Chronic Lymphocytic Leukemia (CLL) Therapeutics – Dormant Products (Contd..5)
Chronic Lymphocytic Leukemia (CLL) Therapeutics – Dormant Products (Contd..6)
Chronic Lymphocytic Leukemia (CLL) Therapeutics – Dormant Products (Contd..7)
Chronic Lymphocytic Leukemia (CLL) Therapeutics – Dormant Products (Contd..8)

List of Figures
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2012
Products under Development for Chronic Lymphocytic Leukemia (CLL) – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2012
• Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2013
• Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2013
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2013
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2012
• HIV / AIDS – Pipeline Review, H1 2013
• Anemia - Pipeline Review, H1 2012
• Diabetic Macular Edema - Pipeline Review, H1 2013
• Inflammatory Bowel Disease - Pipeline Review, H1 2013
• Candidiasis - Pipeline Review, H1 2013